MoFo Life Sciences

April 16, 2020 - United States, COVID-19, United Kingdom, European Union, Healthcare, Intellectual Property
Germany, UK, USA: Are Patent Exceptions the Cure to COVID-19?
By: Wolfgang Schönig, Alistair Maughan and Robert Grohmann
As the COVID-19 pandemic continues to spread globally, the life sciences industry is at the forefront of addressing the urgent need for pharmaceuticals, diagnostics, ventilators, and personal protective equipment capable of helping to contain the surge. While the laws of many countries provide for
... ›
March 24, 2020 - COVID-19, European Union, Regulatory, Intellectual Property
Hard Knocks Keep Coming for Europe’s Unified Patent Court
By: Wolfgang Schönig and Robert Grohmann
With brexited UK announcing that it will not join Europe’s long-awaited Unified Patent Court (UPC), the establishment of an efficient pan-European patent litigation system faces ever‑mounting challenges. Last Friday, the German Federal Constitutional Court declared that the German Act of Approval of the UPC
... ›
February 20, 2020 - United States, Intellectual Property
New USPTO Rule Likely to Increase Spam
By: Muzamil Huq
The United States Patent and Trademark Office (USPTO) just issued new rules that directly affect trademark owners. Going forward, trademark applicants, registrants, and parties to a proceeding before the Trademark Trial and Appeal Board will need to provide their email address in USPTO filings.
... ›
February 13, 2020 - AI + Robotics, European Union, Intellectual Property
CAN AI BE AN INVENTOR? NOT AT THE EUROPEAN PATENT OFFICE
By: Alistair Maughan and Anna Yuan
The European Patent Office has denied two patent applications on the grounds that an AI system cannot be listed as the inventor. For the first time, the European Patent Office (EPO) has issued a ruling on its approach to patent applications that designate artificial
... ›
January 23, 2020 - United States, Agtech, Regulatory, Intellectual Property
Plant Variety Protection Office Now Accepting Applications For Asexually Reproduced Plants
By: Liz Freeman Rosenzweig, Cory Ellison and Michael R. Ward
On January 6, 2020, the Plant Variety Protection Office (PVPO) released the final version of its much-anticipated rule to open Plant Variety Protection (PVP) to asexually reproduced plants. Publication of this rule means that the PVPO is now accepting applications for all species of
... ›
December 19, 2019 - AI + Robotics, Global, Data Analytics, Intellectual Property
Global IP Policy in the Age of AI
By: Karen G Potter
Between 2013 and 2016, the number of Artificial Intelligence (AI) related patent applications in the life sciences and medical sciences grew by about 40% * , and, with continuing advances in technology, has likely increased substantially since 2016. Although this finding may not come
... ›
December 12, 2019 - Licensing + Commercial, Intellectual Property, Asia
Crossing Borders
By: Janet Xiao
Partner Janet Xiao, who leads the firm’s China Life Sciences Group, co-authored an article with associate Can Cui for Intellectual Property Magazine , titled “ Crossing Borders ,” which explores technology transfer opportunities emerging from import rules in China. The authors note that Chinese
... ›
December 09, 2019 - United States, Litigation, Pharma, Intellectual Property
Striking the Balance in Trade Secret and Corporate Espionage Disputes
By: Matthew A. Chivvis
In 2017, the Commission on the Theft of American Intellectual Property issued a report to Congress estimating that the theft of trade secrets could cost the United States economy as much as $600 billion annually. In the years following, news reports indicate that alleged
... ›
November 22, 2019 - United States, FDA, Litigation, Biotech, Healthcare, Pharma, Regulatory, Intellectual Property
FDA Approves 25th Biosimilar
On November 15, Pfizer’s adalimumab product became the 25th biosimilar approved by FDA under the Biologics Price Competition and Innovation Act (BPCIA). The road to the 25th approval has been long and has involved some of the biggest companies and medications in the pharmaceutical
... ›
October 01, 2019 - Licensing + Commercial, Biotech, Regulatory, Intellectual Property, Asia
China Patent Eligibility Update: Human Embryonic Stem Cells
On September 23, 2019, China National Intellectual Property Administration (“CNIPA”) announced its proposed amendments to China’s Guideline on Patent Examination (the “Guideline”), which is the counterpart of the Manual of Patent Examining Procedure in the U.S. The proposed amendments will become effective November 1,
... ›

Topic Archives: Intellectual Property

Germany, UK, USA: Are Patent Exceptions the Cure to COVID-19?

By: Wolfgang Schönig, Alistair Maughan and Robert Grohmann

Hard Knocks Keep Coming for Europe’s Unified Patent Court

By: Wolfgang Schönig and Robert Grohmann

New USPTO Rule Likely to Increase Spam

By: Muzamil Huq

CAN AI BE AN INVENTOR? NOT AT THE EUROPEAN PATENT OFFICE

By: Alistair Maughan and Anna Yuan

Plant Variety Protection Office Now Accepting Applications For Asexually Reproduced Plants

By: Liz Freeman Rosenzweig, Cory Ellison and Michael R. Ward

Global IP Policy in the Age of AI

By: Karen G Potter

Crossing Borders

By: Janet Xiao

Striking the Balance in Trade Secret and Corporate Espionage Disputes

By: Matthew A. Chivvis

FDA Approves 25th Biosimilar

China Patent Eligibility Update: Human Embryonic Stem Cells